Spevigo

— THERAPEUTIC DISORDERS TREATED —
  • Psoriasis

Spevigo Generic Name & Formulations

General Description

Spesolimab-sbzo 450mg/7.5mL (60mg/mL); soln for IV infusion after dilution; preservative-free.

Pharmacological Class

Interleukin-36 receptor antagonist.

How Supplied

Single-dose vials—2

Generic Availability

NO

Spevigo Indications

Indications

Generalized pustular psoriasis (GPP) flares.

Spevigo Dosage and Administration

Adult

900mg as a single dose by IV infusion over 90mins. May give additional 900mg dose after 1 week if flare symptoms persist. 

Children

Not established.

Spevigo Contraindications

Not Applicable

Spevigo Boxed Warnings

Not Applicable

Spevigo Warnings/Precautions

Warnings/Precautions

Increased risk of infections. Consider risks/benefits prior to initiating if chronic or history of recurrent infection. Latent or history of TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Patients with active TB infection: do not initiate. Monitor for active TB during and after therapy. Discontinue immediately if anaphylaxis or other serious hypersensitivity develops (eg, DRESS). Interrupt and consider appropriate treatment if mild or moderate infusion-related reactions develop. Pregnancy. Nursing mothers. 

Spevigo Pharmacokinetics

Metabolism

Catabolism. 

Elimination

Half-life: 25.5 days. 

Spevigo Interactions

Interactions

Avoid concomitant live vaccines. 

Spevigo Adverse Reactions

Adverse Reactions

Asthenia, fatigue, nausea, vomiting, headache, pruritus, prurigo, infusion site hematoma, bruising, urinary tract infection; DRESS. 

Spevigo Clinical Trials

See Literature

Spevigo Note

Not Applicable

Spevigo Patient Counseling

See Literature